UMECLIDINIUM and COUGH

Overview

COUGH is the #3 most commonly reported adverse reaction for UMECLIDINIUM, manufactured by GlaxoSmithKline LLC. There are 701 FDA adverse event reports linking UMECLIDINIUM to COUGH. This represents approximately 3.8% of all 18,218 adverse event reports for this drug.

Patients taking UMECLIDINIUM who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is moderately reported among UMECLIDINIUM users, representing a notable but not dominant share of adverse events.

Other Side Effects of UMECLIDINIUM

In addition to cough, the following adverse reactions have been reported for UMECLIDINIUM:

• DYSPNOEA — 1,352 reports
• DRUG INEFFECTIVE — 752 reports
• ASTHMA — 604 reports
• WRONG TECHNIQUE IN DEVICE USAGE PROCESS — 520 reports
• PNEUMONIA — 509 reports
• CHRONIC OBSTRUCTIVE PULMONARY DISEASE — 403 reports
• FATIGUE — 364 reports
• WHEEZING — 325 reports
• DEATH — 321 reports
• PRODUCT DOSE OMISSION ISSUE — 319 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does UMECLIDINIUM cause COUGH?

COUGH has been reported as an adverse event in 701 FDA reports for UMECLIDINIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with UMECLIDINIUM?

COUGH accounts for approximately 3.8% of all adverse event reports for UMECLIDINIUM, making it one of the most commonly reported side effect.

What should I do if I experience COUGH while taking UMECLIDINIUM?

If you experience cough while taking UMECLIDINIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages